<DOC>
	<DOC>NCT01227564</DOC>
	<brief_summary>This study in individuals with early Alzheimer's disease is designed to assess:(1) safety and tolerability (2) the capacity of ACC-001 and QS-21 adjuvant to reduce brain amyloid load as measured by positron emission tomography (PET) scans.</brief_summary>
	<brief_title>Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>Concern about a change in cognition expressed by the subject or by an informant that knows the subject well MiniMental State Examination (MMSE) score â‰¥ 25 Global Clinical Dementia Rating = 0.5. General cognition and functional performance sufficiently preserved such that a diagnosis of Alzheimer's dementia cannot not be made by the site physician at the time of screening. Amyloid burden detected on screening brain PET scan. Other inclusion criteria apply. Significant neurological disease other than early Alzheimer's disease Major psychiatric disorder or symptom Contraindication to undergo brain MRI Unstable medical conditions Other exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Early Alzheimer's disease</keyword>
	<keyword>active immunization</keyword>
	<keyword>amyloid imaging</keyword>
</DOC>